Kent E Taylor

US Patent:

7790370, Sep 7, 2010

Filed:

Jul 30, 2003

Appl. No.:

10/526256

Inventors:

Maria T. Abreu - New York NY, US
Kent D. Taylor - Ventura CA, US
Jerome I. Rotter - Los Angeles CA, US
Huiying Yang - Cerritos CA, US
Stephan R. Targan - Santa Monica CA, US

Assignee:

Cedars-Sinai Medical Center - Los Angeles CA

International Classification:

C07H 21/04
C12Q 1/68

US Classification:

435 6, 435 911, 435 912, 536 231, 536 243

Abstract:

The present invention provides a method of diagnosing or predicting susceptibility to a clinical subtype of Crohn's disease characterized by fibrostenosing disease by determining the presence or absence in an individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, where the presence of the fibrostenosis-predisposing allele is diagnostic of or predictive of susceptibility to the clinical subtype of Crohn's disease characterized by fibrostenosing disease. In a method of the invention, the clinical subtype of Crohn's disease can be, for example, characterized by fibrostenosing disease independent of small bowel involvement. The invention also provides a method of optimizing therapy in an individual by determining the presence or absence in the individual of a fibrostenosis-predisposing allele linked to a NOD2/CARD15 locus, diagnosing individuals in which the fibrostenosis-predisposing allele is present as having a fibrostenosing subtype of Crohn's disease, and treating the individual having a fibrostenosing subtype of Crohn's disease based on the diagnosis.

US Patent:

61839515, Feb 6, 2001

Filed:

May 12, 1997

Appl. No.:

8/855825

Inventors:

Scott E. Plevy - Tenafly NJ
Stephan R. Targan - Santa Monica CA
Kent Taylor - Santa Paula CA
Mary J. Barry - Ramona CA

Assignee:

Prometheus Laboratories, Inc. - San Diego CA

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

The present invention provides methods based on serological and genetic markers for diagnosing clinical subtypes of Crohn's disease (CD) having characteristic responsiveness to anti-Th1 cytokine therapy. In the methods of the inventions the presence of perinuclear anti-neutrophil antibody (pANCA), the presence of the TNFa10b4c1d3e3 haplotype or the presence TNFa11b4c1d3e3 haplotype each are independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. In addition, the presence of the homozygous TNF-. beta. 1111 haplotype involving the TNFc, aa13L, aa26 and NcoI loci is independently diagnostic of a clinical subtype of CD having an inferior clinical response to anti-Th1 cytokine therapy. The presence of speckling anti-pan polymorphonuclear antibody (SAPPA) is diagnostic of a clinical subtype of CD having a superior clinical response to anti-Th1 cytokine therapy.